Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 May 3;18:953–964. doi: 10.2147/NDT.S358851

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 Meng et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

Changes in MG-ADL and MMS in MuSK-MG patients after treatment with low-dose rituximab during follow-up period. (A) The MG-ADL was significantly declined from 11 (7–15) before rituximab treatment to 0 (0–3, p= 0.011) after treatment. (B) MMS was 38.5 (24–60) at baseline and was improved to 100 (90–100, p=0.012) at last follow-up. *P<0.05; **P<0.01, vs baseline.

Abbreviations: MG-ADL, MG-related activities of daily living; MMS, myasthenic muscle score; MuSK, muscle-specific tyrosine kinase; MG, myasthenia gravis.